A tiny probe into the heart's hidden reserve could forecast who needs a transplant

NCT ID NCT05700617

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This study looks at whether measuring the heart's 'reserve'—its ability to pump harder under stress—can predict how patients with advanced heart failure will do. Five patients with weak hearts (ejection fraction 40% or less) will be randomly assigned to receive the drug milrinone or no drug, while doctors use a catheter to measure pressures and blood flow inside the heart. The goal is to see if these measurements can forecast the need for major therapies like a heart pump or transplant, or the risk of death.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
milrinone
What this could lead to
If successful, this could help doctors better predict which advanced heart failure patients might need more intensive therapies like a heart pump or transplant.
What could go wrong
This is a very small early-phase study with only 5 participants, so results may not apply broadly. The invasive catheter procedure carries risks, and the drug may not reliably predict outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOGENIC SHOCK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The University of Chicago

    RECRUITING

    Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.